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SUnited States Food and Drug Administration and our insti-
tutional review board for permission to implant TEVGs in
humans with single ventricle physiology.
In conclusion, this trial demonstrates the feasibility of us-
ing tissue-engineering technology to create vascular grafts
for use as extracardiac TCPCs. Inasmuch as stenosis is the pri-
mary mode of graft failure on TEVGs, further follow-up and
investigation for the mechanism of stenosis are warranted.
Continued study regarding themechanisms of TEVG stenosis
will allow us to generate the next generation of TEVGs.References
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Dr John Edmund Mayer, Jr (Boston, Mass). You have some
patients who have not survived long term in your tissue-engineered
extracardiac Fontan group. Do you have any histologic studies on
those explanted grafts from autopsy?
Dr Hibino. Unfortunately, for these TCPC graft-implanted pa-
tients, the families declined autopsies; therefore, we do not have
the histologic information. We have the histologic data, however,
from reoperation patients. In these patients we used a tissue engi-
neered graft as a patch for pulmonary angioplasty in a stenosed
region. After the angioplasty, pulmonary artery stenosis developed
again, including the portion replaced with the TEVG. Here is the
histology of the explanted graft at reoperation. In this image we
note endothelialization of the tissue and smooth muscle layer for-
mation, which suggests neotissue formation.ery c February 2010
